These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19676147)

  • 1. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease.
    Mesquita M; Demulder A; Damry N; Mélot C; Wittersheim E; Willems D; Dratwa M; Bergmann P
    Clin Chem Lab Med; 2009; 47(3):339-46. PubMed ID: 19676147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients.
    Morena M; Dupuy AM; Jaussent I; Vernhet H; Gahide G; Klouche K; Bargnoux AS; Delcourt C; Canaud B; Cristol JP
    Nephrol Dial Transplant; 2009 Nov; 24(11):3389-97. PubMed ID: 19574342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
    Morena M; Jaussent I; Dupuy AM; Bargnoux AS; Kuster N; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
    Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
    Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
    J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients.
    Kurnatowska I; Grzelak P; Kaczmarska M; Stefańczyk L; Nowicki M
    Nephron Clin Pract; 2011; 117(4):c297-304. PubMed ID: 20861651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease.
    Mesquita M; Demulder A; Wolff F; Mélot C; Damry N; Dratwa M; Bergmann P
    Transplant Proc; 2010 Nov; 42(9):3444-9. PubMed ID: 21094794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
    Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
    Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
    Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
    Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients.
    Mikami S; Hamano T; Fujii N; Nagasawa Y; Isaka Y; Moriyama T; Matsuhisa M; Ito T; Imai E; Hori M
    Hypertens Res; 2008 Jun; 31(6):1163-70. PubMed ID: 18716364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Value of Osteoprotegerin for Detecting Coronary Artery Calcification in Type 2 Diabetes Mellitus Patients in Correlation with Extent of Calcification Detected by Multidetector Computed Tomography.
    Ahmed S; Sobh R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(6):845-851. PubMed ID: 30747085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder.
    Jiang JQ; Lin S; Xu PC; Zheng ZF; Jia JY
    Nephrology (Carlton); 2011 Aug; 16(6):588-94. PubMed ID: 21649792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial.
    Bjerre M; Hilden J; Kastrup J; Skoog M; Hansen JF; Kolmos HJ; Jensen GB; Kjøller E; Winkel P; Flyvbjerg A; Gluud C;
    Scand J Clin Lab Invest; 2014 Nov; 74(8):657-64. PubMed ID: 25026506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects.
    Stępień E; Fedak D; Klimeczek P; Wilkosz T; Banyś RP; Starzyk K; Bazanek M; Pasowicz M
    Hypertens Res; 2012 May; 35(5):531-8. PubMed ID: 22278625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification.
    Sigrist MK; Levin A; Er L; McIntyre CW
    Nephrol Dial Transplant; 2009 Oct; 24(10):3157-62. PubMed ID: 19491380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients.
    Morena M; Jaussent I; Halkovich A; Dupuy AM; Bargnoux AS; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
    PLoS One; 2012; 7(5):e36175. PubMed ID: 22567137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention.
    Siller-Matula J; Lang IM; Schoergenhofer C; Roest M; Jilma B
    Thromb Haemost; 2017 Aug; 117(9):1730-1738. PubMed ID: 28726980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiopoietin-2 levels predict mortality in CKD patients.
    David S; John SG; Jefferies HJ; Sigrist MK; Kümpers P; Kielstein JT; Haller H; McIntyre CW
    Nephrol Dial Transplant; 2012 May; 27(5):1867-72. PubMed ID: 21976741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.
    Poornima IG; Mackey RH; Buhari AM; Cauley JA; Matthews KA; Kuller LH
    Menopause; 2014 Jul; 21(7):702-10. PubMed ID: 24473535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes.
    Maser RE; Lenhard MJ; Sneider MB; Pohlig RT
    Endocr Pract; 2015 Jan; 21(1):14-22. PubMed ID: 25100392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of coronary artery calcification with renal function decline and mortality in predialysis chronic kidney disease patients.
    Lamarche MC; Hopman WM; Garland JS; White CA; Holden RM
    Nephrol Dial Transplant; 2019 Oct; 34(10):1715-1722. PubMed ID: 30010904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.